Unknown

Dataset Information

0

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.


ABSTRACT: BACKGROUND:This study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of brivanib in patients with advanced/metastatic solid tumors. PATIENTS AND METHODS:Ninety patients enrolled in this two-part, phase I open-label study of oral brivanib alaninate. The primary objectives of this study were (in part A) dose-limiting toxicity, maximum tolerated dose (MTD) and the lowest biologically active dose level and (in part B) the optimal dose/dose range. The secondary objectives of this study were preliminary evidence of antitumor activity, PK and PD. RESULTS:Across part A (open-label dose escalation and MTD) and part B (open-label dose optimization), 68 patients received brivanib alaninate. Brivanib demonstrated a manageable toxicity profile at doses of 180-800 mg. Most toxic effects were mild. Systemic exposure of the active moiety brivanib increased linearly ?1000 mg/day. The MTD was 800 mg/day. Forty-four patients were treated at the MTD: 20 with 800 mg continuously, 11 with 800 mg intermittently and 13 with 400 mg b.i.d. doses. Partial responses were confirmed in two patients receiving brivanib ?600 mg. Dynamic contrast-enhanced magnetic resonance imaging demonstrated statistically significant decreases in parameters reflecting tumor vascularity and permeability after multiple doses in the 800-mg continuous q.d. and 400-mg b.i.d. dose cohorts. CONCLUSION:In patients with advanced/metastatic cancer, brivanib demonstrates promising antiangiogenic and antitumor activity and manageable toxicity at doses ?800 mg orally q.d., the recommended phase II study dose.

SUBMITTER: Jonker DJ 

PROVIDER: S-EPMC3139984 | biostudies-literature | 2011 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.

Jonker D J DJ   Rosen L S LS   Sawyer M B MB   de Braud F F   Wilding G G   Sweeney C J CJ   Jayson G C GC   McArthur G A GA   Rustin G G   Goss G G   Kantor J J   Velasquez L L   Syed S S   Mokliatchouk O O   Feltquate D M DM   Kollia G G   Nuyten D S A DSA   Galbraith S S  

Annals of oncology : official journal of the European Society for Medical Oncology 20101203 6


<h4>Background</h4>This study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of brivanib in patients with advanced/metastatic solid tumors.<h4>Patients and methods</h4>Ninety patients enrolled in this two-part, phase I open-label study of oral brivanib alaninate. The primary objectives of this study were (in part A) dose-limiting toxicity, maximum tolerated dose (MTD) and the lowest biologically active dose level and (in part B) the optimal dose/dose range.  ...[more]

Similar Datasets

| S-EPMC2967392 | biostudies-literature
| S-EPMC7417410 | biostudies-literature
| S-EPMC5705193 | biostudies-literature
| S-EPMC7066280 | biostudies-literature
| S-EPMC3137402 | biostudies-literature
| S-EPMC7024606 | biostudies-literature
| S-EPMC4302229 | biostudies-literature
| S-EPMC3016151 | biostudies-literature
| S-EPMC4433501 | biostudies-literature
| S-EPMC3461162 | biostudies-literature